Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CGEN NASDAQ:KURA NASDAQ:OPT NASDAQ:RAPP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCGENCompugen$1.44-1.4%$1.62$1.13▼$2.66$130.29M2.61249,939 shs381,765 shsKURAKura Oncology$5.96-1.2%$6.21$5.41▼$21.57$522.04M0.411.30 million shs989,884 shsOPTOpthea$3.41+7.2%$3.41$1.79▼$6.30$524.84M1.17N/A3,000 shsRAPPRapport Therapeutics$15.41+5.5%$13.09$6.43▼$29.74$533.23M0.62161,905 shs334,257 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCGENCompugen-1.37%-0.69%-15.29%+14.29%-11.66%KURAKura Oncology-1.16%-1.49%+2.58%+3.29%-67.91%OPTOpthea0.00%0.00%0.00%0.00%+57.87%RAPPRapport Therapeutics+5.48%+7.31%+22.11%+50.34%-18.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCGENCompugen1.6728 of 5 stars3.54.00.00.00.70.00.0KURAKura Oncology3.258 of 5 stars3.41.00.04.70.00.80.6OPTOptheaN/AN/AN/AN/AN/AN/AN/AN/ARAPPRapport Therapeutics1.7824 of 5 stars3.50.00.00.03.10.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCGENCompugen 3.00Buy$4.00177.78% UpsideKURAKura Oncology 2.86Moderate Buy$24.50311.07% UpsideOPTOpthea 2.17Hold$1.33-60.90% DownsideRAPPRapport Therapeutics 3.00Buy$29.5091.43% UpsideCurrent Analyst Ratings BreakdownLatest CGEN, OPT, KURA, and RAPP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/6/2025RAPPRapport TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$31.007/8/2025RAPPRapport TherapeuticsJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.006/26/2025KURAKura OncologyCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight6/20/2025KURAKura OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$36.006/4/2025KURAKura OncologyJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$28.005/19/2025KURAKura OncologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$32.00 ➝ $30.00(Data available from 8/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCGENCompugen$27.86M4.61N/AN/A$0.62 per share2.32KURAKura Oncology$53.88M9.58N/AN/A$5.32 per share1.12OPTOpthea$120K4,373.61N/AN/A($0.56) per share-6.09RAPPRapport TherapeuticsN/AN/AN/AN/A$8.35 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCGENCompugen-$14.23M-$0.22N/AN/AN/A-87.45%-33.67%-16.41%N/AKURAKura Oncology-$173.98M-$2.10N/AN/AN/AN/A-43.62%-29.13%N/AOPTOpthea-$220.24MN/A0.00N/AN/AN/AN/AN/A8/29/2025 (Estimated)RAPPRapport Therapeutics-$78.31M-$3.45N/AN/AN/AN/A-25.48%-24.63%8/14/2025 (Estimated)Latest CGEN, OPT, KURA, and RAPP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025RAPPRapport Therapeutics-$0.87-$0.75+$0.12-$0.75N/AN/A8/7/2025Q2 2025KURAKura Oncology$0.15-$0.75-$0.90-$0.75$64.95 million$15.29 million8/6/2025Q2 2025CGENCompugen-$0.07-$0.08-$0.01-$0.08$3.95 million$1.26 million5/19/2025Q1 2025CGENCompugen-$0.06-$0.08-$0.02-$0.08$3.70 million$2.28 million5/8/2025Q1 2025RAPPRapport Therapeutics-$0.77-$0.68+$0.09-$0.68N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCGENCompugenN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/AOPTOptheaN/AN/AN/AN/AN/ARAPPRapport TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCGENCompugenN/A5.095.09KURAKura Oncology0.028.078.07OPTOptheaN/A1.57N/ARAPPRapport TherapeuticsN/A31.0131.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCGENCompugen12.22%KURAKura OncologyN/AOPTOpthea55.95%RAPPRapport TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipCGENCompugen9.50%KURAKura Oncology6.40%OPTOpthea3.20%RAPPRapport TherapeuticsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCGENCompugen7089.24 million80.76 millionOptionableKURAKura Oncology13086.57 million81.03 millionOptionableOPTOpthea8153.91 million148.99 millionNot OptionableRAPPRapport TherapeuticsN/A36.50 millionN/AN/ACGEN, OPT, KURA, and RAPP HeadlinesRecent News About These CompaniesRapport Therapeutics (NASDAQ:RAPP) Now Covered by Analysts at HC WainwrightAugust 7 at 8:38 AM | marketbeat.comRapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business UpdateAugust 7 at 7:00 AM | globenewswire.comRapport Therapeutics (RAPP) Expected to Announce Earnings on ThursdayAugust 7 at 2:51 AM | marketbeat.comHC Wainwright & Co. Initiates Coverage of Rapport Therapeutics (RAPP) with Buy RecommendationAugust 6 at 3:30 PM | msn.comRapport Therapeutics initiated with a Buy at H.C. WainwrightAugust 6 at 3:30 PM | msn.comRapport Therapeutics Inc. (RAPP) Stock Price Today - WSJJuly 26, 2025 | wsj.comRapport Therapeutics (NASDAQ:RAPP) Stock Price Up 9.1% - Here's WhyJuly 25, 2025 | marketbeat.comRapport Therapeutics, Inc. (NASDAQ:RAPP) Insider Sells $119,000.00 in StockJuly 16, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading Up 5.3% - Time to Buy?July 16, 2025 | marketbeat.comAI therapy bots fuel delusions and give dangerous advice, Stanford study findsJuly 11, 2025 | arstechnica.comARapport Therapeutics (NASDAQ:RAPP) Shares Down 6.3% - Should You Sell?July 11, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Trading 9.8% Higher - Here's WhyJuly 9, 2025 | marketbeat.comRapport Therapeutics (NASDAQ:RAPP) Receives "Market Outperform" Rating from JMP SecuritiesJuly 8, 2025 | marketbeat.comRapport Therapeutics stock rating reiterated as Buy by TD CowenJuly 2, 2025 | uk.investing.comAnalysts Can't Get Enough of These Little-Known Biopharma Stocks (RAPP)...June 12, 2025 | marketbeat.comStifel reiterates buy rating for Rapport Therapeutics stockJune 5, 2025 | uk.investing.comRapport Therapeutics Hosts Inaugural Investor and Analyst Day to Update on RAP-219 and Clinical PipelineJune 4, 2025 | nasdaq.comRapport Therapeutics Hosts Investor and Analyst Day; Provides Corporate UpdatesJune 2, 2025 | globenewswire.comRapport Therapeutics to Participate in the Jefferies Global Healthcare Conference and Goldman Sachs 46th Annual Global Healthcare ConferenceMay 27, 2025 | globenewswire.comRapport Therapeutics to Host 2025 Investor and Analyst DayMay 21, 2025 | globenewswire.comCompanies Like Rapport Therapeutics (NASDAQ:RAPP) Are In A Position To Invest In GrowthMay 16, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesRocket Lab: A Parabolic Run Meets a Healthy PullbackBy Ryan Hasson | July 23, 2025View Rocket Lab: A Parabolic Run Meets a Healthy PullbackPelosi Makes Big Bet on Broadcom—Here’s Why It MattersBy Gabriel Osorio-Mazilli | July 15, 2025View Pelosi Makes Big Bet on Broadcom—Here’s Why It MattersPalantir Gets Price Hike From Wedbush Amid High ValuationBy Chris Markoch | July 15, 2025View Palantir Gets Price Hike From Wedbush Amid High ValuationPalantir Bulls and Bears Set for an August Showdown By Chris Markoch | July 22, 2025View Palantir Bulls and Bears Set for an August Showdown CSX Stock Rally: Strong Options Flow, Analyst Price TargetsBy Jeffrey Neal Johnson | July 18, 2025View CSX Stock Rally: Strong Options Flow, Analyst Price TargetsCGEN, OPT, KURA, and RAPP Company DescriptionsCompugen NASDAQ:CGEN$1.44 -0.02 (-1.37%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.46 +0.02 (+1.04%) As of 08/7/2025 07:02 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.Kura Oncology NASDAQ:KURA$5.96 -0.07 (-1.16%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$5.92 -0.04 (-0.76%) As of 08/7/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Opthea NASDAQ:OPT$3.41 +0.23 (+7.23%) As of 08/6/2025Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead product candidate is Sozinibercept (OPT 302), a soluble form of vascular endothelial growth factor receptor-3 VEGFR-3, currently under Phase 3 clinical development as a novel therapy for wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.Rapport Therapeutics NASDAQ:RAPP$15.41 +0.80 (+5.48%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$15.42 +0.02 (+0.10%) As of 08/7/2025 06:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Constellation Energy’s Earnings Beat Signals a New Era AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down Realty Income Rallies Post-Earnings Miss—Here’s What Drove It Don't Mix the Signal for Noise in Super Micro Computer's Earnings Microsoft Stock Gains as Analysts Boost Price Targets Joby Deal Gives Blade New Direction, But Stock Lacks Lift Uber Technologies Is Driving Cash Flow: Ride It Higher for Life How DigitalOcean's Focus Is Fueling Explosive Growth Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
